Effect of Belimumab on Antibody Titers in Primary APS Patients
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Positive for high-titer antiphospholipid antibodies according to the criteria of the "EULAR Guidelines for the Treatment of Antiphospholipid Syndrome in Adults" published in 2019. * Stable APS regimen according to EULAR recommendations for antiphospholipid syndrome. * Female patients who are not pregnant, breastfeeding, of childbearing potential, or not using contraception. Exclusion Criteria: * Patients with a history of malignant tumor in the past 5 years, except for basal cell carcinoma or squamous cell carcinoma of skin or cervical carcinoma in situ treated locally, and there is no evidence of metastasis within 3 years; * Patients with a history of primary immunodeficiency; * Serious lack of IgG (IgG level \< 400 mg/dL); * IgA deficiency (IgA level \< 10 mg/dL); * Patients with a current history of infection; * Patients with a current history of drug or alcohol abuse or dependence, or have a history of drug or alcohol abuse or depen